Trulicity’s performance was a big positive for Lilly however, as there had been speculation that it might start to slow down thanks to the challenge from Ozempic – which has outperformed it in ...

Eli Lilly has scored a major victory in its battle for the US diabetes drug market after a trial showed its Trulicity cut risk of cardiovascular events, even in patients who had no prior history ...

The 40-week study — sponsored by Eli Lilly, the manufacturer of both drugs — aimed to address this question. Researchers compared the safety and efficacy of gradually escalating Trulicity ...